Exchange: NASDAQ·Updated 03:53 PM EDT

About ABEO

About

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
226

Frequently Asked Questions

What is Market Cap of Abeona Therapeutics Inc?
What is the 52-week high for Abeona Therapeutics Inc?
What is the 52-week low for Abeona Therapeutics Inc?
What is Abeona Therapeutics Inc stock price today?
What was Abeona Therapeutics Inc stock price yesterday?
What is the PE ratio of Abeona Therapeutics Inc?
What is the Price-to-Book ratio of Abeona Therapeutics Inc?
What is the 50-day moving average of Abeona Therapeutics Inc?
How many employees does Abeona Therapeutics Inc have?

Advertisement|Remove ads.